Citation

Janssen-Aguilar R, Rojas P, Ruiz-Sánchez E, Rodríguez-Violante M, Alcántara-Flores YM, Crail-Melendez D, Cervantes-Arriaga A, Sánchez-Escandón, Ruiz-Chow A. Brain Sci. 2022; 12(3): e326.

Copyright

(Copyright © 2022, Switzerland Molecular Diversity Preservation International (MDPI) AG)

DOI

10.3390/brainsci12030326

PMID

35326281

Abstract

Major depressive disorder (MDD) is a major health problem in Parkinson's disease (PD) patients. We described the clinical and sociodemographic factors of MDD among patients with PD at a national neurological referral center in Mexico. One hundred patients with PD + MDD were included in the study. All the patients were evaluated during the "ON" treatment phase of PD. Clinical scales for cognition (MMSE and MoCA) and MDD (MADRS) were applied. The mean age was 58.49 ± 11.02 years, and 57% of the sample was male. The most frequent symptom of PD was tremor (67%), and onset was more frequent on the right side (57%). Additionally, 49% of the patients with PD had moderate to severe (M/S) MDD. Selective serotonin reuptake inhibitors were the most frequent antidepressant treatment (69%). The scores of the scales were MADRS 21.33 ± 5.49, MoCA 21.06 ± 4.65, and MMSE 26.67 ± 1.20. The females had lower MMSE scores compared to the males (p = 0.043). The patients with M/S MDD had more rigidity at the beginning of PD (p = 0.005), fewer march alterations (p = 0.023), and a greater prevalence of left-side initial disease (p = 0.037). Rigidity was associated with M/S MDD (OR 3.75 p = 0.013). MDD was slightly more frequent in the males than in the females. The MDD symptoms and cognitive impairment were worse in the female population.

Language: en

Keywords

major depressive disorder; neurodegenerative disease; non-motor symptoms; Parkinson’s disease